China, India Seen As Trend-Setters In Emerging Market Pharma Growth
This article was originally published in PharmAsia News
Executive Summary
China is expected to be among the leaders of a growing trend of growth in the global pharmaceutical industry being led by the emerging markets. That realization has attracted the attention of multinational and domestic drug makers that seek to benefit from the new markets that include China and India as well as Mexico and Turkey. IMS China Health Market Research Consulting said in a report that China's pharmaceutical market should continue growing at the rate of 20 percent this year, although down from the 26 percent registered in 2008, thanks in part to new health care reforms. China's health minister said changes in the nation's health-insurance coverage of essential drugs has expanded to include a much larger portion of the population based on average urban income level. (Click here for more
You may also be interested in...
The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews
Oncologic Drugs Advisory Committee was swayed by views of its disease area experts in favorably reporting out Geron’s imetelstat for myelodysplastic syndromes and supplemental applications for the CAR-T products Carvykti and Abecma in earlier lines of multiple myeloma.
Demi Moore’s Wonderbelly Antacid Investment Lands Supporting Role In Her Promotional Posts
Wonderbelly Antacids “free from” ad claims work but failing to disclose Demi Moore is an investor in her promotions doesn’t, NAD says. Dakota Nutrition fails again on NAD’s test of its testing for elderberry in its supplements.
UroGen Approaches A Big Expansion In Bladder Cancer
The oncology company is preparing for the launch of UGN-102 for bladder cancer. CEO Liz Barrett talked to Scrip about the company’s next growth phase.